Pazopanib

For research use only. Not for use in humans.

Catalog No.S3012 Synonyms: GW786034

31 publications

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pazopanib has been cited by 31 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell NIXBXlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HUdGlvcGmkaYTpc44hd2ZiaIXtZY4hTW:OLUGtZ4VtdCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDpZ|UxRTJwOEnlMVA2KM7:TR?= MV;TRW5ITVJ?
human AN3-CA cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUjzd2t3UW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> NH\qT4VUSU6JRWK=
human CGTH-W-1 cell NYPJSZlIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX3ydolZUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRyLkCxJI5O NYDkdGgxW0GQR1XS
human GDM-1 cell NUDyT|d{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXCWJUxUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExOy57OTDuUS=> MmriV2FPT0WU
human A204 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXZNI82UW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVA6NjB4IH7N M17RdnNCVkeHUh?=
human G-402 cell MojnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH\xcmlKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVMyNjh2IH7N MVjTRW5ITVJ?
human MFE-296 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6ODJ{IN88US=> NYfOOWZjW0GQR1XS
human NOS-1 cell NVOxVJVtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHS4XIpKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKGmlNUC9NE43PTl6NzFOwG0> M3n2cnNCVkeHUh?=
human KG-1 cell NIrtXIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HESmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4PTVizszN NIHrc|VUSU6JRWK=
human HT55 cell M1ruRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfyZ|BKdmirYnn0bY9vKG:oIHj1cYFvKEiWNUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PzhzIN88US=> NWHUTWJnW0GQR1XS
human MG-63 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;CTmlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> MojCV2FPT0WU
human CCF-STTG1 cell NUDFSmxTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rEcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD1zLkC0PVgyKM7:TR?= NW\VPWRRW0GQR1XS
human RT-112 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M37wVWlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> MXnTRW5ITVJ?
human MC-IXC cell NHjrU5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN MWrTRW5ITVJ?
human HUTU-80 cell Mm[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWf0dIZiUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OEGwN{DPxE1? NXvnTnJRW0GQR1XS
human MV-4-11 cell NWDYVoc1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1PTBzIN88US=> Mn7iV2FPT0WU
human LCLC-103H cell M{jwUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 MXPTRW5ITVJ?
human G-401 cell NHvV[ZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWfJN|ZIUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZ2MkGg{txO NHS3U2tUSU6JRWK=
human A704 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXfJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[wN|I{KM7:TR?= MlTSV2FPT0WU
human ESS-1 cell M4HsZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= NFrPU3VUSU6JRWK=
human HLE cell NFnreGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jTV2lvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62N|gxPCEQvF2= NIOyTlZUSU6JRWK=
human NY cell NGiwRpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHUTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOES4NlEh|ryP NVLlUHk6W0GQR1XS
human A427 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVfYRnZjUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QDB5NTFOwG0> MWTTRW5ITVJ?
human SK-N-DZ cell NYL1O5pXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoTxTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVTaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOjN6MTFOwG0> M3v6dHNCVkeHUh?=
human J82 cell M4PYVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWS1OpFnUW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA3ODh6IN88US=> M1r3OHNCVkeHUh?=
human GI-1 cell Moi5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M320ZmlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN NGf3[m1USU6JRWK=
human NCI-H716 cell M3PBcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2nYPGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjNzNkOzJO69VQ>? MVHTRW5ITVJ?
human SF126 cell NXfNc4J[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj60O|Q2QSEQvF2= MYfTRW5ITVJ?
human H4 cell NIHyfnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HmOWlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxNlYzKM7:TR?= M4HrOnNCVkeHUh?=
human LB831-BLC cell NHX2elJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrLTY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? MVPTRW5ITVJ?
human HCC1395 cell NYS3PJZST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnXDTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzM{m1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42QDF3NjFOwG0> MYnTRW5ITVJ?
human LK-2 cell NGLnbphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjjN2V[UW6qaXLpeIlwdiCxZjDoeY1idiCOSz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk43PDV4OTFOwG0> NITJS5FUSU6JRWK=
human G-361 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3zTppVUW6qaXLpeIlwdiCxZjDoeY1idiCJLUO2NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODRyOEKg{txO MnPuV2FPT0WU
human NCI-H2342 cell M4PDS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\WdWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwIFnDOVA:Oy5zM{OxOkDPxE1? NXjzdWRNW0GQR1XS
human SK-LU-1 cell  MkHTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXTZSol3UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? Ml7yV2FPT0WU
human IGROV-1 cell  M3K4N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVTaNGN2UW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5{NEexN{DPxE1? MlzUV2FPT0WU
human EB2 cell MofDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF25bIpKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN MV\TRW5ITVJ?
human CAL-54 cell NUTh[GZ7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN MVPTRW5ITVJ?
human LB1047-RCC cell MnrwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHPGXHhKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOzNzM{[4JO69VQ>? MYrTRW5ITVJ?
Daudi cell MnjPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnKfm1KdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkWzNVY1KM7:TR?= M1HRNXNCVkeHUh?=
human Daudi cell NUXBdo1sT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHf5RY1KdmirYnn0bY9vKG:oIHj1cYFvKESjdXTpJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43PjJzOTFOwG0> NU\XS5ZFW0GQR1XS
human A172 cell M{O4WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33pUWlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|M4QSEQvF2= M4fUS3NCVkeHUh?=
human KGN cell MlnPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmjMTY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2O|A6KM7:TR?= NVTVXmRYW0GQR1XS
human SNG-M cell M2Hl[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml3YTY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNFg3PjlizszN MYLTRW5ITVJ?
human SW1710 cell M3q0dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4TMfWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> MVTTRW5ITVJ?
human HT29 cells M37NS3Bzd2yrZnXyZZRqd25iYYPzZZk> M4LycWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= NXLUZphbOTh4MkCzPFI>
human A375P cells NULNV21{WHKxbHnm[ZJifGmxbjDhd5NigQ>? M4PSXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= MkXYNVg3OjB|OEK=
human HN5 cells M{fXbXBzd2yrZnXyZZRqd25iYYPzZZk> MkX4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTkWgZ4VtdHNiaX6gd4VzfW1iY3;ueIFqdmmwZzDt[YRqfW1? NXX0[VNHOTh4MkCzPFI>
HUVEC NHnLWJJHfW6ldHnvckBie3OjeR?= M1TDUVEh|ryP MXe2JIg> MWjBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? NHO5OJkzPDB|NkC0Ni=>
human Daoy cell MlXxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NES0fHpKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc4QTR7IN88US=> MYnTRW5ITVJ?
human DMS-273 cell MkjwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHabplnUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57NkKwNkDPxE1? NFW4TVlUSU6JRWK=
human KU812 cell M{Hn[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnITllKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzhzMjFOwG0> Mon3V2FPT0WU
human NCI-H727 cell NV;uXWRwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XRcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjRyOUCxJO69VQ>? MUfTRW5ITVJ?
human P30-OHK cell NXT6OJg4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mm\uTY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41Pjl2IN88US=> MnfPV2FPT0WU
human MIA-PaCa-2 cell MlLYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVLscnRiUW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62NFQ3PiEQvF2= MmnTV2FPT0WU
human TT cell NYX6WmFOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFjmTXFKdmirYnn0bY9vKG:oIHj1cYFvKFSWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OlI1KM7:TR?= MWfTRW5ITVJ?
human DK-MG cell NXH0coNnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGRMNU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63NlAzQCEQnH2= MVXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA ; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in (A) RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

27924057
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034
Smiles C[N]1N=C2C=C(C=CC2=C1C)N(C)C3=NC(=NC=C3)NC4=CC=C(C)C(=C4)[S](N)(=O)=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT02979899 Completed Biological: TRC105|Drug: Votrient Advanced Angiosarcoma Tracon Pharmaceuticals Inc. February 13 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID